Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HRTX
stocks logo

HRTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
38.08M
+5.69%
-0.013
-79.17%
39.03M
+18.96%
-0.015
-50%
39.83M
-2.34%
-0.020
-200%
Estimates Revision
The market is revising Downward the revenue expectations for Heron Therapeutics, Inc. (HRTX) for FY2025, with the revenue forecasts being adjusted by -1.12% over the past three months. During the same period, the stock price has changed by 0.00%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.12%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+118.18%
In Past 3 Month
Stock Price
No Change
down Image
0.00%
In Past 3 Month
Wall Street analysts forecast HRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRTX is 4.50 USD with a low forecast of 3.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast HRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRTX is 4.50 USD with a low forecast of 3.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.310
sliders
Low
3.00
Averages
4.50
High
6.00
Current: 1.310
sliders
Low
3.00
Averages
4.50
High
6.00
Jefferies
Buy
downgrade
$6 -> $5
2025-11-04
Reason
Jefferies
Price Target
$6 -> $5
2025-11-04
downgrade
Buy
Reason
Jefferies lowered the firm's price target on Heron Therapeutics to $5 from $6 and keeps a Buy rating on the shares. Zynrelef delivered Q3 net revenue of $9.3M, ahead of the consensus view of $9M, driven by rising demand, vial access needle transition, improved access, and enhanced support programs, the analyst tells investors in a research note. The firm added that its price target, which is based on a DCF valuation model, is also driven by oncology franchise sales, with peak sales of $106M in 2025.
H.C. Wainwright
Brandon Folkes
Buy
initiated
$6
2025-06-09
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$6
2025-06-09
initiated
Buy
Reason
Needham
Serge Belanger
Strong Buy
Reiterates
$4
2025-04-11
Reason
Needham
Serge Belanger
Price Target
$4
2025-04-11
Reiterates
Strong Buy
Reason
Needham
Serge Belanger
Strong Buy
Reiterates
$4
2025-02-28
Reason
Needham
Serge Belanger
Price Target
$4
2025-02-28
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Heron Therapeutics Inc (HRTX.O) is -74.86, compared to its 5-year average forward P/E of -93.62. For a more detailed relative valuation and DCF analysis to assess Heron Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-93.62
Current PE
-74.86
Overvalued PE
308.27
Undervalued PE
-495.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.53
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.73
Undervalued EV/EBITDA
-9.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.33
Current PS
0.00
Overvalued PS
8.54
Undervalued PS
0.12
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

HRTX News & Events

Events Timeline

(ET)
2025-12-04
08:20:00
Heron Therapeutics' APONVIE Included in New PONV Management Guidelines
select
2025-11-04 (ET)
2025-11-04
08:04:45
Heron Therapeutics projects FY25 revenue between $153M and $163M, with consensus at $156.48M.
select
2025-11-04
08:04:01
Heron Therapeutics announces Q3 earnings per share of 10 cents, surpassing consensus estimate of 1 cent.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04Yahoo Finance
PinnedHeron Therapeutics Reveals APONVIE® (aprepitant) Injectable Emulsion Added to Updated Fifth Consensus Guidelines for Postoperative Nausea and Vomiting (PONV) Management

  • APONVIE Overview: APONVIE is the only FDA-approved IV formulation of the NK-1 antagonist aprepitant, indicated for preventing postoperative nausea and vomiting (PONV) in adults, with a rapid onset and long half-life compared to oral alternatives.

  • Efficacy in PONV Prevention: Aprepitant, whether used alone or in combination with other therapies, significantly reduces the risk of PONV and is more effective than 5-HT3 receptor antagonists, making it a preferred choice for postoperative care.

  • Guidelines for Postoperative Care: The newly released PONV Guidelines emphasize the importance of long-acting antiemetics like APONVIE to mitigate post-discharge nausea and vomiting (PDNV), which affects a significant number of patients after surgery.

  • Clinical Implications: The guidelines advocate for a multimodal approach to PONV prevention, particularly for high-risk patients, highlighting the need for clinicians to be aware of and adhere to these recommendations to enhance patient recovery experiences.

[object Object]
Preview
5.0
12-04Globenewswire
Heron Launches APONVIE for Rapid Prevention of Postoperative Nausea and Vomiting
  • FDA Approval: APONVIE is the only FDA-approved IV NK-1 antagonist, enabling rapid administration in 30 seconds, significantly reducing the risk of postoperative nausea and vomiting (PONV) by 30%, thereby enhancing patient satisfaction post-surgery.
  • Clinical Guidelines Recognition: APONVIE's inclusion in the latest Consensus Guidelines for the Management of Postoperative Nausea and Vomiting underscores its critical role in multimodal prophylaxis, reflecting broad clinical acceptance and solidifying Heron's leadership in the biopharmaceutical sector.
  • Market Opportunity: With an increasing number of surgeries performed in outpatient and short-stay settings, APONVIE presents substantial market potential to help reduce postoperative complications, enhancing patient confidence at home and potentially increasing Heron's market share and brand influence.
  • Long-term Impact: By promoting APONVIE, Heron aims to improve postoperative recovery experiences for patients while encouraging clinicians to utilize long-acting antiemetics before discharge, thereby further decreasing the incidence of PONV and enhancing overall healthcare quality.
[object Object]
Preview
4.0
11-13NASDAQ.COM
Daily Upgrade Report for Validea's James P. O'Shaughnessy Strategy - November 13, 2025

  • Validea's Growth/Value Investor Model: The model, based on James P. O'Shaughnessy's strategy, evaluates large-cap value and growth stocks, with a recent upgrade for Heron Therapeutics Inc (HRTX) from 75% to 100% due to strong fundamentals and valuation.

  • Company Overview: Heron Therapeutics is a biotechnology company focused on developing therapeutic innovations for acute care and oncology, with products like ZYNRELEF, APONVIE, CINVANTI, and SUSTOL aimed at improving patient care.

  • Investment Strategy Insights: O'Shaughnessy's research challenges traditional investment beliefs, emphasizing that price/earnings ratios may not be the best value indicators and that small-cap stocks do not necessarily outperform large-cap stocks.

  • Validea's Research Service: Validea provides investment analysis and model portfolios based on the strategies of renowned investors, aiming to help users identify stocks that have historically outperformed the market.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Heron Therapeutics Inc (HRTX) stock price today?

The current price of HRTX is 1.31 USD — it has increased 3.15 % in the last trading day.

arrow icon

What is Heron Therapeutics Inc (HRTX)'s business?

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.

arrow icon

What is the price predicton of HRTX Stock?

Wall Street analysts forecast HRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRTX is 4.50 USD with a low forecast of 3.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Heron Therapeutics Inc (HRTX)'s revenue for the last quarter?

Heron Therapeutics Inc revenue for the last quarter amounts to 38.21M USD, increased 16.47 % YoY.

arrow icon

What is Heron Therapeutics Inc (HRTX)'s earnings per share (EPS) for the last quarter?

Heron Therapeutics Inc. EPS for the last quarter amounts to -0.10 USD, increased 233.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Heron Therapeutics Inc (HRTX)'s fundamentals?

The market is revising Downward the revenue expectations for Heron Therapeutics, Inc. (HRTX) for FY2025, with the revenue forecasts being adjusted by -1.12% over the past three months. During the same period, the stock price has changed by 0.00%.
arrow icon

How many employees does Heron Therapeutics Inc (HRTX). have?

Heron Therapeutics Inc (HRTX) has 122 emplpoyees as of December 05 2025.

arrow icon

What is Heron Therapeutics Inc (HRTX) market cap?

Today HRTX has the market capitalization of 238.37M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free